Table 1.
Clinical, demographic and laboratory characteristics of the study patients.
| Characteristic | Study Group | ||||
|---|---|---|---|---|---|
| CHIKV Infection | Control Group | ||||
| Detected via Serum RT-qPCR (N = 19) |
Detected via IgM Seroconversion between Paired Samples (N = 12) |
Detected via IgM in the Acute-Phase Sample (N = 20) |
DENV Infection Detected via Serum RT-qPCR (N = 16) |
Non-Arbovirus Diseases (N = 28) |
|
| n/N (%) or median (interquartile range) | |||||
| DEMOGRAPHICS | |||||
| Sex (F) | 10/19 (53%) | 6/12 (50%) | 13/20 (65%) | 11/16 (69%) | 14/28 (50%) |
| Age | 40 (32–47) | 32 (20–52) | 35 (21–42.5) | 24 (20–34) | 31.5 (18.5–43) |
| Days after symptom onset | 3 (1–4) | 4 (1–5) | 4 (3–6) | 2.5 (1–3) | 4 (3–7) |
| CLINICAL MANIFESTATIONS | |||||
| Fever | 19/19 (100%) | 11/12 (92%) | 17/20 (85%) | 16/16 (100%) | 26/28 (93%) |
| Arthralgia | 18/19 (95%) | 9/12 (75%) | 17/20 (85%) | 12/16 (75%) | 13/28 (46%) |
| Myalgia | 18/19 (95%) | 10/12 (83%) | 17/20 (85%) | 14/16 (88%) | 15/28 (54%) |
| Headache | 18/19 (95%) | 9/12 (75%) | 18/20 (90%) | 14/16 (88%) | 23/28 (82%) |
| Retro-orbital pain | 12/19 (63%) | 7/12 (58%) | 10/20 (50%) | 11/16 (69%) | 8/28 (29%) |
| Conjunctival hyperemia | 9/19 (47%) | 3/12 (25%) | 6/20 (30%) | 10/16 (63%) | 9/28 (32%) |
| Swollen joints | 12/19 (63%) | 5/12 (42%) | 11/20 (55%) | 2/16 (13%) | 2/28 (7%) |
| Pruritus | 10/19 (53%) | 5/12 (45%) | 15/20 (75%) | 7/16 (44%) | 8/28 (29%) |
| Rash | 5/18 (28%) | 4/12 (33%) | 14/20 (70%) | 5/16 (31%) | 5/28 (18%) |
| Sore throat | 7/19 (37%) | 2/12 (17%) | 6/20 (30%) | 7/16 (44%) | 12/28 (43%) |
| Cough | 5/19 (26%) | 4/12 (33%) | 3/20 (15%) | 5/16 (31%) | 21/28 (75%) |
| Abdominal pain | 5/19 (26%) | 6/12 (50%) | 7/20 (35%) | 7/16 (44%) | 15/28 (54%) |
| CHIKV RT-qPCR RESULTS | |||||
| SERUM | |||||
| Positive | 19/19 (100%) | 0/12 (0%) | 0/20 (0%) | 0/16 (0%) | 0/28 (0%) |
| Cycle threshold | 24.5 (22.7–28.3) | - | - | - | - |
| ORAL FLUID | |||||
| Positive | 9/19 (47%) | 2/12 (17%) | 0/20 (0%) | 0/16 (0%) | 0/28 (0%) |
| Cycle threshold | 36.6 (36.2–37.5) | 32.9 (31.5–34.3) | - | - | - |
| URINE | |||||
| Positive | 1/19 (5%) | 0/12 (0%) | 0/20 (0%) | 0/16 (0%) | 0/28 (0%) |
| Cycle threshold | 34.4 (34.4–34.4) | - | - | - | - |